From Our Partners
Sunday, June 26, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Medical Countermeasures

Positive Results for Combination Ricin, Anthrax Vaccine

by Global Biodefense Staff
July 14, 2014
Biodefense Vaccine Development

Credit: Shutterstock

Soligenix, Inc. last week announced positive results for the combination of RiVax and VeloThrax to induce protective immunity to both ricin toxin and anthrax toxin exposure.

RiVax is the company’s candidate vaccine for the prevention of exposure to ricin toxin using a unique antigen that is completely devoid of the toxic activity of ricin. VeloThrax employs a derivative of recombinant protective antigen, termed Dominant Negative Inhibitor (DNI), which is a candidate for inclusion in a next generation anthrax vaccine.

When administered as single a vaccine, each vaccine induced antibodies that were capable of neutralizing the toxin from which the vaccine had been derived.  VeloThrax induced neutralizing antibodies against anthrax toxin and RiVax induced antibodies against ricin toxin.  When combined, the dual vaccine induced antibodies that were reactive against both toxins and these neutralizing antibodies were detected until at least 200 days after the immunization regimens.

Consequently, the combined vaccination provided protection to exposure to both ricin toxin and anthrax toxin that persisted for at least six months after 2 vaccinations, suggesting that long-term immunity upon simultaneous vaccination can be achieved.

Soligenix performed these studies in collaboration with the Wadsworth Institute of the New York State Department of Health, with Dr. Nicolas J. Mantis, Dr. David Vance and collaborators under the aegis of a $9.4 million cooperative grant from the National Institute of Allergy and Infectious Diseases (NIAID). The potency of the vaccine combination was demonstrated in preclinical studies evaluating both production of antibody levels and survival after toxin challenge.

“We are pleased that we have been able to show that the combination of vaccines for these two very important biothreats can be accomplished.  The demonstration of simultaneous immunity to ricin toxin and anthrax is a step towards multivalent vaccines that can be used in the event of a national emergency,” stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix.

“Both of these vaccines are being developed for military personnel and emergency first responders, and thus it would be extremely useful if the vaccines could be administered simultaneously without compromising the response to either vaccine, while still providing protection against whichever toxin might be encountered,” said Schaber. “Multivalent vaccines will achieve more efficient vaccination with fewer injections; this has the potential to be a distinct advantage in deployment of vaccines if any biothreat agent is actually used as a weapon and will be more useful for vaccination of military personnel and first responders. We intend to develop the combination vaccine using ThermoVax, our proprietary system for stabilizing vaccines for stockpiling and for distribution of vaccines outside of normal cold chain requirements.”

Source: Soligenix, Inc. press release, adapted. RiVax and VeloThrax and ThermoVax are trademarked terms of Soligenix.

From Our Partners
Tags: AnthraxBioterrorismNIAIDRicinStrategic National StockpileThermostabilityVaccines

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Medical Countermeasures

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

May 30, 2022
Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors
Industry News

Novavax Missed Its Global Moonshot but Is Angling to Win Over mRNA Defectors

May 26, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC